NASDAQ$CRMD
CorMedix Inc · Q1 2020 earnings
Q1 2020 earnings · · Investor relations
Briefing
Reported financial results for Q1 2020 and provided a business update.
CorMedix reported a net loss of $5.6 million, or $0.21 per share, for the first quarter of 2020. The company's operating expenses increased by $0.7 million, driven by higher SG&A expenses, partially offset by a $0.1 million increase in gross profit on sales. The Company reported cash and short term investments of $23.2 million at March 31, 2020.
- Net loss for Q1 2020 was $5.6 million, or $0.21 per share.
- Operating expenses increased by $0.7 million, primarily due to higher SG&A expenses.
- Cash and short term investments were $23.2 million as of March 31, 2020.
- Company maintains guidance for an anticipated decision on approval of the NDA in the second half of 2020.
Headline financials
Revenue & EPS history
CorMedix · Revenue · Quarterly
$74.1K
Forward guidance
The Company believes that, based on its current cash resources, it has sufficient resources to fund operations into the second quarter of 2021, including initial preparations for commercial launch.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2020
-1.3%
Avg return
Earnings day
+1.1%
Avg return
5 days after
+12.4%
Avg return
30 days after
43%
20 / 47 earnings
Positive
+31.1%
Q3 2022
Best reaction
-31.8%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +5.7% | +4.4% | +16.7% | |
| Q4 2025 | -11.7% | -5.6% | -1.0% | |
| Q3 2025 | +2.1% | -10.8% | +2.7% | |
| Q1 2025 | +23.6% | +29.1% | +46.0% | |
| Q4 2024 | -31.8% | +13.8% | +98.2% | |
| Q3 2024 | -22.4% | -26.1% | -24.0% | |
| Q2 2024 | +27.0% | +36.5% | +83.9% | |
| Q1 2024 | -9.5% | -6.7% | -9.6% | |
| Q4 2023 | +10.8% | +8.2% | +81.5% | |
| Q3 2023 | +7.1% | +28.9% | +10.9% | |
| Q2 2023 | +6.1% | +7.3% | -8.5% | |
| Q1 2023 | -13.9% | -1.5% | +5.2% | |
| Q4 2022 | +13.1% | +16.4% | +35.0% | |
| Q3 2022 | +31.1% | +30.4% | +33.6% | |
| Q2 2022 | +22.8% | +26.6% | +10.1% | |
| Q1 2022 | +7.6% | +25.7% | -3.3% | |
| Q4 2021 | +3.4% | -1.4% | -37.6% | |
| Q3 2021 | +0.4% | -0.4% | -6.0% | |
| Q2 2021 | +7.1% | +4.2% | -21.7% | |
| Q1 2021 | -23.1% | -16.9% | +4.6% | |
| Q4 2020 | +15.0% | +16.1% | -1.4% | |
| Q3 2020 | -0.9% | +5.7% | +61.0% | |
| Q2 2020 | -0.5% | +5.6% | +10.0% | |
| Q1 2020 | -6.9% | -2.7% | +54.2% | |
| Q4 2019 | -22.5% | -31.3% | -3.8% | |
| Q3 2019 | +6.1% | +28.2% | +25.8% | |
| Q2 2019 | -2.8% | -0.6% | -3.6% | |
| Q1 2019 | -7.7% | -0.4% | +8.7% | |
| Q4 2018 | -1.6% | -14.6% | -0.5% | |
| Q3 2018 | -15.5% | +9.1% | +27.3% | |
| Q2 2018 | -21.7% | -25.0% | -1.7% | |
| Q1 2018 | -5.0% | -5.0% | +60.0% | |
| Q4 2017 | -19.4% | -32.3% | -32.3% | |
| Q3 2017 | +3.8% | -9.4% | +5.7% | |
| Q2 2017 | -5.4% | -2.7% | +16.2% | |
| Q1 2017 | -5.8% | -5.8% | -15.4% | |
| Q4 2016 | -12.2% | -22.0% | -40.5% | |
| Q3 2016 | -18.6% | -22.1% | -23.0% | |
| Q2 2016 | -7.1% | -8.4% | +18.8% | |
| Q1 2016 | -11.7% | — | — | |
| Q4 2015 | -5.2% | — | — | |
| Q3 2015 | -3.2% | — | — | |
| Q2 2015 | -3.8% | — | — | |
| Q1 2015 | — | — | — | |
| Q2 2014 | +5.9% | — | — | |
| Q2 2013 | +24.4% | — | — | |
| Q4 2013 | -1.2% | — | — | |
| Q2 2010 | +7.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro